Showing results (61-70 of 71) with videos related to
Sort By:
Pageof 8
Hepatology (Baltimore, Md.)|February 8, 2017
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registryCarlos Fernández Carrillo, Sabela Lens, Elba Llop, et al.Revista Espanola De Enfermedades Digestivas|December 14, 2022
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liverJoaquín Cabezas, Javier Crespo, Antonio Aguilera, et al.Journal of Hepatology|March 10, 2020
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASHJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.Journal of Hepatology|June 17, 2019
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAsJordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, et al.Alimentary Pharmacology & Therapeutics|May 2, 2024
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvirJuan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, et al.Liver International : Official Journal of the International Association for the Study of the Liver|April 25, 2021
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjectsJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.Journal of Gastroenterology|April 15, 2024
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosisJavier Ampuero, Rocío Aller, Rocío Gallego-Durán, et al.Liver International : Official Journal of the International Association for the Study of the Liver|May 9, 2017
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4Zoe Mariño, Juan M Pascasio-Acevedo, Adolfo Gallego, et al.Journal of Hepatology|May 11, 2025
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialCynthia Levy, George F Abouda, Bahri M Bilir, et al.Digestive Diseases and Sciences|February 3, 2023
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis BBeatriz Mateos-Muñoz, María Buti, Inmaculada Fernández Vázquez, et al.Pageof 8